Fixed-dose administration and pharmacokinetically guided adjustment of busulfan dose for patients undergoing hematopoietic stem cell transplantation: a meta-analysis and cost-effectiveness analysis-Reference-Cited by-同舟云学术

Fixed-dose administration and pharmacokinetically guided adjustment of busulfan dose for patients undergoing hematopoietic stem cell transplantation: a meta-analysis and cost-effectiveness analysis

Published:2022-01-29 Issue:3 Volume:101 Page:667-679
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Chen Tingting,Chen Chaoxin,He Xin,Guo Jianming,Liu Maobai,Zheng Bin

Funder

Fujian Provincial Department of Science and Technology

Joint Funds for the innovation of science and Technology, Fujian province

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04733-3.pdf

Reference29 articles.

1. Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF et al (2016) Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 22:1424–1430

2. Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M et al (2010) Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 115(22):4597–4604

3. Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS et al (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84(5):321–330

4. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al (2004) Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857–886

5. Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M et al (2016) Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant 22(11):1915–1925

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen;Transplantation and Cellular Therapy;2024-07

2. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients;Therapeutic Drug Monitoring;2024-06-14

3. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT;Transplantation and Cellular Therapy;2023-12

4. Chemotherapy;Medicines for Cancer;2023